{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-137853","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.804388+00:00","generated_at":"2026-05-19T17:25:48.054399+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Lyell Immunopharma appoints Mark Bachleda to Board, expanding size to 8","bullets":["Board increased from 7 to 8 directors; Mark Bachleda, Pharm.D., M.B.A., appointed as Class I director effective June 9, 2025.","Term expires at 2028 annual meeting; compensation per non-employee director policy adjusted for 1-for-20 reverse stock split.","Standard indemnification agreement entered with Dr. Bachleda."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-137853","json":"https://secwatch.observer/filing/0001193125-25-137853.json","markdown":"https://secwatch.observer/filing/0001193125-25-137853.md","text":"https://secwatch.observer/filing/0001193125-25-137853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525137853/0001193125-25-137853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525137853/d940968d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T17:25:48.054399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c18a9128c","claim":"Mark Bachleda was appointed as Director at Lyell Immunopharma, Inc..","evidence_excerpt":"on June 9, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) increased the authorized size of the Board from seven directors to eight directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mark Bachleda, Pharm.D., M.B.A., to the Board as a Class I director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525137853/0001193125-25-137853-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}